Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Lumakras
Pharma
Verastem nixes KRAS G12C plans in non-small cell lung cancer
Newer G12C inhibitors are “establishing a new benchmark with higher response rates,” Verastem’s chief medical officer said in explaining the move.
Angus Liu
Jan 2, 2026 10:10am
Vyvgart, Cabenuva, Lumakras top Trinity launch success analysis
Mar 12, 2025 2:13pm
AZ's Calquence, Amgen's Lumakras win new FDA green lights
Jan 17, 2025 11:11am
BMS and Mirati's KRAS inhibitor Krazati moves beyond NSLC
Jun 24, 2024 8:53am
ASCO: BMS' confirmatory KRAS data leave FDA prospects unclear
Jun 1, 2024 8:00am
Amgen CEO nabs pay raise thanks to Horizon deal
Apr 18, 2024 5:08pm
